Company intelligence / Profile preview

Ricacell

Ownership: Private
Development stage: Other

Overview

Ricacell is a biotechnology company specializing in the development of circular RNA (circRNA) therapeutics and vaccines. Headquartered in Suzhou, China, the company leverages its proprietary Rica-circ platform to engineer RNA molecules with enhanced stability and reduced immunogenicity compared to traditional linear mRNA. Ricacell's integrated approach combines advanced circRNA design with specialized lipid nanoparticle (LNP) delivery systems to target oncology and infectious diseases. Founded in 2021, the company is backed by prominent venture capital firms including Legend Capital and BioTrack Capital. Ricacell aims to advance its preclinical pipeline into human trials to address significant unmet medical needs globally.

Therapeutic areas: Infectious DiseasesOncology
Modalities: RNA therapyBiologicLipid nanoparticle delivery therapy
Industry: Biotech

Beyond the preview

Go deeper on Ricacell.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Ricacell.

Explore the full profile